Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Repeat Dose Study of AGN-150998 in Exudative Age-related Macular Degeneration
2011-002526-43Phase 2Completed
- Sponsor
- Allergan
- Start
- Aug 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of abicipar pegol in age-related macular degeneration (AMD) (2 arms), sponsored by Allergan. Primary endpoints: Maximum tolerated dose of AGN-150998 (Stage 1) and Efficacy endpoints. Started Aug 2011; status: completed.
02
Drugs
abicipar pegol
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2011-002526-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002526-43.